Vous êtes ici

Pharmadrug Inc.

Liste d'échange: 
CSE
Statut: 
Active
Industrie: 
Life Sciences
Symbole: 
PHRX
Indice CSE: 
Devise: 

PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs. PharmaDrug owns 100% of Pharmadrug Production GmbH (“Pharmadrug Production”), a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the European Union. PharmaDrug owns 100% Sairiyo Therapeutics (“Sairiyo”), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Company also owns 100% of Super Smart, a company building a vertically integrated retail business with the goal to elevate the use of functional mushrooms as natural based medicines.

Vous êtes ici

Pharmadrug Inc. (PHRX)

SEDAR Information

Information d'entreprise

Addresse
77 King St. West, Suite 2905
Toronto, ON M5K 1H1
Canada
Téléphone
647-202-1824
Fax
416-765-0029
Courriel
info@aurahealthinc.com
URL
http://www.pharmadrug.com
Date d’inscription à la cote
Jeudi, août 16, 2018
Agent de transfert
Capital Transfer Agency

Capitalisation

Capitalisation: 
104556647
Réservé à l'émission: 
15240323

Company Officers

Robert Steen, CEO
Kyle Appleby, CFO

Bulletins

20/10/2023

2023-1038 – Consolidation - Pharmadrug Inc. (PHRX)

le 20 octobre/October 2023

Pharmadrug Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every seven (7) pre-consolidated common shares.

As a result, the outstanding shares of the company will be reduced to approximately 51,518,049 common shares.

The name and symbol will not change.